You are here

Article info

Article menu
Clinical and epidemiological research
Extended report
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

Authors

  1. Correspondence to Dr G R Burmester, Clinic for Rheumatology and Clinical Immunology, Charité Humboldt University, Schumannstrasse 20/21, 10117 Berlin, Germany; gerd.burmester{at}charite.de
View Full Text

Citation

Burmester GR, Mease P, Dijkmans BAC, et al
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
Annals of the Rheumatic Diseases 2009;68:1863-1869.

Publication history

  • Accepted January 2, 2009
  • First published January 15, 2009.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Burmester et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.